HCPLive

Related Tags

Higher Dose of Fulvestrant Associated With Improved Survival in Advanced Breast Cancer

Postmenopausal women with advanced estrogen receptor–positive breast cancer lived longer when they received a 500-mg dose of fulvestrant as compared with a 250-mg dose.

Click here to view this article.


Most Popular

Recommended Reading

For women with breast cancer, embryo cryopreservation after aromatase inhibitor treatment and ovarian stimulation preserves fertility, according to a study published online June 22 in the Journal of Clinical Oncology.

Glucocorticoids and other 3-ketosteroids may adversely affect patients with mixed estrogen receptor (ER) α-positive/cytokeratin-5 (CK5) breast cancer, according to a study published online June 22 in Oncogene.

For breast cancer survivors, a yoga and meditation intervention is associated with improvement in menopausal symptoms, according to a study published in the July 1 issue of Cancer.

The percentage of women with early-stage breast cancer who undergo breast-conserving therapy (BCT) has risen slowly in recent years, new research shows.
$vAR$